Casaasdas

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Por um escritor misterioso
Last updated 03 abril 2025
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Disease Control Data, Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Disease Control Data, Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
PDF) Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Axial Spondyloarthritis RINVOQ® (upadacitinib)
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Frontiers Targeted Therapies in Axial Psoriatic Arthritis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Management of axial spondyloarthritis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Management of axial spondyloarthritis
Recomendado para você
você pode gostar

© 2014-2025 startwindsor.com. All rights reserved.